{
  "1": "",
  "2": "",
  "3": "",
  "4": "",
  "5": "",
  "6": "",
  "7": "\u003Cp\u003EHarbeck N, Penault-Llorca F, Cortes J, et al. Breast cancer. Nat Rev Dis Primers. 2019 Sep 23;5(1):66. doi: 10.1038/s41572-019-0111-2. PMID: 31548545.\u003C/p\u003E",
  "8": "\u003Cp\u003EHarbeck N. Risk-adapted adjuvant therapy of luminal early breast cancer in 2020. CurrOpinObstet Gynecol. 2021;33:53-58. doi: 10.1097/GCO.0000000000000679. PMID: 33337614.\u003C/p\u003E",
  "9": "\u003Cp\u003ELoibl S, Marm\u00E9 f, Martin, M, et al. Phase III study of palbociclib combined with endocrine therapy (ET) in patients with hormone-receptor-positive (HR\u002B), HER2-negative primary breast cancer and with high relapse risk after neoadjuvant chemotherapy (NACT): First results from PENELOPE-B . San Antonio Breast Cancer Symposium;December 8-11, 2020; San Antonio, TX. Abstract GS01-02.\u003C/p\u003E",
  "10": "",
  "11": "\u003Cp\u003EDenkert C, Marm\u00E9 F, Martin M, et al. Subgroup of post-neoadjuvant luminal-B tumors assessed by HTG in PENELOPE-B investigating palbociclib in high risk HER2-/HR\u002B breast cancer with residual disease. Presented at: ASCO 2021 Annual Meeting; June 4-8, 2021. Abstract 519.\u003C/p\u003E",
  "12": "\u003Cp\u003EMarm\u00E9 F, Martin M, Untch M, et al. Palbociclib combined with endocrine treatment in breast cancer patients with high relapse risk after neoadjuvant chemotherapy: Subgroup analyses of premenopausal patients in PENELOPE-B. ASCO 2021 Annual Meeting; June 4-8, 2021. Abstract 518. \u003C/p\u003E",
  "13": "\u003Cp\u003EMayer E, et al. PALLAS: A randomized phase III trial of adjuvant palbociclib with endocrine therapy versus endocrine therapy alone for HR\u002B/HER2- early breast cancer. Presented at: European Society for Medical Oncology (ESMO) congress. Virtual 2020. Abstract LBA12.\u003C/p\u003E",
  "14": "\u003Cp\u003EO\u2019Shaughnessy JA, Johnston S, Harbeck N, et al. Primary outcome analysis of invasive disease-free survival for monarchE: abemaciclib combined with adjuvant endocrine therapy for high risk early breast cancer. San Antonio Breast Cancer Symposium;December 8-11, 2020; San Antonio, TX. Abstract GS01-01.\u003C/p\u003E",
  "15": "",
  "16": "",
  "17": "\u003Cp\u003EET = endocrine therapy\u003C/p\u003E\u003Cp\u003EITT = intention-to-treat\u003C/p\u003E\u003Cp\u003ENAC = neoadjuvant chemotherapy\u003C/p\u003E\u003Cp\u003EMartin M, Hegg R, Kim SB, et al. Abemaciclib combined with adjuvant endocrine therapy in patients with high risk early breast cancer who received neoadjuvant chemotherapy (NAC). Presented at: The American Society of Clinical Oncology (ASCO) 2021 Annual Meeting Virtual; June 4-8, 2021; Abstract 517.\u003C/p\u003E",
  "18": "\u003Cp\u003EET = endocrine therapy\u003C/p\u003E\u003Cp\u003EIDFS = invasive disease-free survival\u003C/p\u003E\u003Cp\u003ENAC = neoadjuvant chemotherapy\u003C/p\u003E\u003Cp\u003EDRFS = in distant relapse-free survival\u003C/p\u003E\u003Cp\u003EMartin M, Hegg R, Kim SB, et al. Abemaciclib combined with adjuvant endocrine therapy in patients with high risk early breast cancer who received neoadjuvant chemotherapy (NAC). Presented at: The American Society of Clinical Oncology (ASCO) 2021 Annual Meeting Virtual; June 4-8, 2021; Abstract 517.\u003C/p\u003E",
  "19": "\u003Cp\u003EET = endocrine therapy\u003C/p\u003E\u003Cp\u003EIDFS = invasive disease-free survival\u003C/p\u003E\u003Cp\u003ENAC = neoadjuvant chemotherapy\u003C/p\u003E\u003Cp\u003EDRFS = in distant relapse-free survival\u003C/p\u003E\u003Cp\u003EMartin M, Hegg R, Kim SB, et al. Abemaciclib combined with adjuvant endocrine therapy in patients with high risk early breast cancer who received neoadjuvant chemotherapy (NAC). Presented at: The American Society of Clinical Oncology (ASCO) 2021 Annual Meeting Virtual; June 4-8, 2021; Abstract 517.\u003C/p\u003E",
  "20": "\u003Cp\u003EDRFS = in distant relapse-free survival\u003C/p\u003E\u003Cp\u003EEBC = early breast cander\u003C/p\u003E\u003Cp\u003EET = endocrine therapy\u003C/p\u003E\u003Cp\u003EIDFS = invasive disease-free survival\u003C/p\u003E\u003Cp\u003ENAC = neoadjuvant chemotherapy\u003C/p\u003E\u003Cp\u003EGluz O, NitzU, Christgen M, et al Prognostic impact of recurrence score (RS) Results, Endocrine Response and Clinical-pathological Factors in High-risk Luminal Early Breast Cancer: Results from the WSG-ADAPT HR\u002B/HER2- Chemotherapy Trial (CT). Presented at: The American Society of Clinical Oncology (ASCO) 2021 Annual Meeting Virtual; June 4-8, 2021; Abstract 504.\u003C/p\u003E",
  "21": "\u003Cp\u003Ec/p = \u003C/p\u003E\u003Cp\u003EDRFS = in distant relapse-free survival\u003C/p\u003E\u003Cp\u003EET = endocrine therapy\u003C/p\u003E\u003Cp\u003EIDFS = invasive disease-free survival\u003C/p\u003E\u003Cp\u003ERS = recurrence score\u003C/p\u003E\u003Cp\u003EGluz O, Nitz U, Kuemmel S, et al. Prognostic impact of recurrence score, endocrine response and clinical-pathological factors in high-risk luminal breast cancer: Results from the WSG-ADAPT HR\u002B/HER2-chemotherapy trial. Presented at: ASCO 2021 Annual Meeting; June 4-8, 2021. Abstract 504.\u003C/p\u003E",
  "22": "\u003Cp\u003EIDFS = invasive disease-free survival\u003C/p\u003E\u003Cp\u003EReferences: \u003C/p\u003E\u003Cp\u003EGluz O, NitzU, Christgen M, et al Prognostic impact of recurrence score (RS) Results, Endocrine Response and Clinical-pathological Factors in High-risk Luminal Early Breast Cancer: Results from the WSG-ADAPT HR\u002B/HER2- Chemotherapy Trial (CT). Presented at: The American Society of Clinical Oncology (ASCO) 2021 Annual Meeting Virtual; June 4-8, 2021; Abstract 504.\u003C/p\u003E",
  "23": "\u003Cp\u003EER = estrogen receptor\u003C/p\u003E\u003Cp\u003EET = endocrine therapy\u003C/p\u003E\u003Cp\u003EHR =? \u003C/p\u003E\u003Cp\u003EDDFS = distant disease-free survival\u003C/p\u003E\u003Cp\u003EIDFS = invasive disease-free survival\u003C/p\u003E\u003Cp\u003EIHC = immunohistochemistry\u003C/p\u003E\u003Cp\u003EITT = intention-to-treat \u003C/p\u003E\u003Cp\u003EPgR =\u00A0progesterone receptors\u003C/p\u003E\u003Cp\u003EOS = overall survival \u003C/p\u003E\u003Cp\u003EQoL = quality of life\u003C/p\u003E\u003Cp\u003ETNBC  = triple negative breast cancer\u003C/p\u003E\u003Cp\u003ETutt A, Garber JE, Kaufman B, et al. OlympiA: A phase III, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients with germline BRCA1/2 mutations and high-risk HER2-negative early breast cancer. Presented at: The American Society of Clinical Oncology (ASCO) 2021 Annual Meeting Virtual; June 4-8, 2021; Abstract LBA1.\u003C/p\u003E",
  "24": "\u003Cp\u003ER = estrogen receptor\u003C/p\u003E\u003Cp\u003EET = endocrine therapy\u003C/p\u003E\u003Cp\u003EHR =? \u003C/p\u003E\u003Cp\u003EDDFS = distant disease-free survival\u003C/p\u003E\u003Cp\u003EIDFS = invasive disease-free survival\u003C/p\u003E\u003Cp\u003EIHC = immunohistochemistry\u003C/p\u003E\u003Cp\u003EITT = intention-to-treat \u003C/p\u003E\u003Cp\u003EPgR =\u00A0progesterone receptors\u003C/p\u003E\u003Cp\u003EOS = overall survival \u003C/p\u003E\u003Cp\u003EQoL = quality of life\u003C/p\u003E\u003Cp\u003ETNBC  = triple negative breast cancer\u003C/p\u003E\u003Cp\u003EReferences: \u003C/p\u003E\u003Cp\u003ETutt A, Garber JE, Kaufman B, et al. OlympiA: A phase III, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients with germline BRCA1/2 mutations and high-risk HER2-negative early breast cancer. Presented at: The American Society of Clinical Oncology (ASCO) 2021 Annual Meeting Virtual; June 4-8, 2021; Abstract LBA1.\u003C/p\u003E",
  "25": "",
  "26": "",
  "27": "",
  "28": "",
  "29": "",
  "30": "\u003Cp\u003EBC = breast cancer\u003C/p\u003E\u003Cp\u003EFinn RS, Dering J, Conklin D, et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro.\u00A0Breast Cancer Res. 2009;11(5):R77. doi:10.1186/bcr2419\u003C/p\u003E",
  "31": "\u003Cp\u003EFry DW, Harvey PJ, Keller PR, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther. 2004;3:1427-1438. PMID: 15542782.\u003C/p\u003E\u003Cp\u003EGelbert LM, Cai S, Lin X, et al. Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine. Invest New Drugs. 2014;32:825-837. doi: 10.1007/s10637-014-0120-7. Epub 2014 Jun 13. PMID: 24919854; PMCID: PMC4169866.\u003C/p\u003E\u003Cp\u003EKim S,\u00A0Loo A,\u00A0Chopra R,\u00A0Caponigro G, et al. Abstract PR02: LEE011: An orally bioavailable, selective small molecule inhibitor of CDK4/6\u2013 Reactivating Rb in cancer. Mol Cancer Ther2013;12(11 Suppl):PR02.\u003C/p\u003E",
  "32": "\u003Cp\u003ERugo HS, Finn RS, Di\u00E9ras V, et al. Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up. Breast Cancer Res Treat. 2019;174:719-729. \u003C/p\u003E\u003Cp\u003EHortobagyi GN, Stemmer SM, Burris HA, et al. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol. 2018;29:1541-1547. \u003C/p\u003E\u003Cp\u003E\u00A0\u003C/p\u003E\u003Cp\u003Ec. Tripathy D, Im SA, Colleoni M, Franke F, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 2018;19:904-915. \u003C/p\u003E\u003Cp\u003Ed. Im SA, Lu YS, Bardia A, et al. Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer. N Engl J Med. 2019;381:307-316.\u003C/p\u003E\u003Cp\u003E\u00A0\u003C/p\u003E\u003Cp\u003Ee. Goetz MP, Toi M, Campone M, et al. MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. J Clin Oncol. 2017;35:3638-3646. \u003C/p\u003E\u003Cp\u003E\u00A0\u003C/p\u003E\u003Cp\u003Ef. Cristofanilli M, Turner NC, Bondarenko I, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016;17:425-439. \u003C/p\u003E\u003Cp\u003Eg. Turner NC, Slamon DJ, Ro J, et al. Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer. N Engl J Med. 2018 Nov 15;379(20):1926-1936. \u003C/p\u003E\u003Cp\u003E\u00A0\u003C/p\u003E\u003Cp\u003EH. Slamon DJ, Neven P, Chia S, et al. Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer. N Engl J Med. 2020;382:514-524.\u003C/p\u003E\u003Cp\u003Ei. Sledge GW Jr, Toi M, Neven P, et al. MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR\u002B/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. J Clin Oncol. 2017;35(25):2875-2884.\u003C/p\u003E\u003Cp\u003Ei. Sledge GW Jr, Toi M, Neven P, et al. The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial. JAMA Oncol. 2019;6:116\u2013124. \u003C/p\u003E\u003Cp\u003Ek. IBRANCE\u00AE (pablociclib) [prescribing information]. Pfizer, Inc. Approved 2015. Revised April 2019.\u003C/p\u003E\u003Cp\u003El. KISQALI\u00AE (ribociclib) [prescribing information]. Novartis Pharmaceuticals Corp. Approved 2017. Revised March 2017.\u003C/p\u003E\u003Cp\u003Em. Verzenio\u00AE (abemaciclib) [prescribing information]. Eli Lilly and Company. Approved 2017. Revised September 2017.\u003C/p\u003E\u003Cp\u003E\u00A0\u003C/p\u003E\u003Cp\u003ECDK = cyclin-dependent kinase\u003C/p\u003E\u003Cp\u003EPFS=progression-free survival\u003C/p\u003E\u003Cp\u003EOS=overall survival\u003C/p\u003E\u003Cp\u003EAI=aromatase inhibitor\u003C/p\u003E\u003Cp\u003EFulv=fulvestrant\u003C/p\u003E\u003Cp\u003ENR=not reported\u003C/p\u003E",
  "33": "\u003Cp\u003EHurvitz S, IM SA, Lu YS, et al. Phase III MONALEESA-7 trial of premenopausal patients with HR\u002B/HER2- advanced breast cancer treated with endocrine therapy with and without ribociclib: Overall survival results. Presented at: ASCO 2019 Annual Meeting; May 31-June 4; Chicago, IL. Abstract LBA1008. \u003C/p\u003E\u003Cp\u003E\u00A0\u003C/p\u003E",
  "34": "\u003Cp\u003EctDNA = circulating tumor DNA\u003C/p\u003E\u003Cp\u003EESR1=estrogen receptor 1 gene\u003C/p\u003E\u003Cp\u003EFUL=fulvestrant\u003C/p\u003E\u003Cp\u003EMut=mutation\u003C/p\u003E\u003Cp\u003EOS=overall survival\u003C/p\u003E\u003Cp\u003EPAL=palbociclib\u003C/p\u003E\u003Cp\u003EPBO=placebo\u003C/p\u003E\u003Cp\u003EWT=wild-type\u003C/p\u003E\u003Cp\u003ECristofanilli M, et al. Presented at: ASCO Virtual; 2021. Abstract 1000.\u003C/p\u003E\u003Cp\u003ECristofanilli M, Rugo SH, Im SA, et al. Overall Survival With Palbociclib \u002B Fulvestrant in Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Updated Analyses From PALOMA-3. Presented at: The American Society of Clinical Oncology (ASCO) 2021 Annual Meeting Virtual; June 4-8, 2021; Abstract 1000.\u003C/p\u003E",
  "35": "\u003Cp\u003EctDNA = circulating tumor DNA\u003C/p\u003E\u003Cp\u003EFUL = fulvestrant; \u003C/p\u003E\u003Cp\u003EMut = mutation;\u003C/p\u003E\u003Cp\u003E PIK3CA = phosphatidylinositol 3-kinase catalytic subunit alpha gene; \u003C/p\u003E\u003Cp\u003EWT = wild-type. \u003C/p\u003E\u003Cp\u003ECristofanilli M, et al. Presented at: ASCO Virtual; 2021. Abstract 1000.\u003C/p\u003E\u003Cp\u003ECristofanilli M, Rugo SH, Im SA, et al. Overall Survival With Palbociclib \u002B Fulvestrant in Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Updated Analyses From PALOMA-3. Presented at: The American Society of Clinical Oncology (ASCO) 2021 Annual Meeting Virtual; June 4-8, 2021; Abstract 1000.\u003C/p\u003E",
  "36": "\u003Cp\u003EctDNA = circulating tumor DNA\u003C/p\u003E\u003Cp\u003EESR1=estrogen receptor 1 gene\u003C/p\u003E\u003Cp\u003EFUL=fulvestrant\u003C/p\u003E\u003Cp\u003EMut=mutation\u003C/p\u003E\u003Cp\u003EOS=overall survival\u003C/p\u003E\u003Cp\u003EPAL=palbociclib\u003C/p\u003E\u003Cp\u003EPBO=placebo\u003C/p\u003E\u003Cp\u003ETP53 = tumor protein 53 gene\u003C/p\u003E\u003Cp\u003EWT=wild-type\u003C/p\u003E\u003Cp\u003ECristofanilli M, et al. Presented at: ASCO Virtual; 2021. Abstract 1000.\u003C/p\u003E\u003Cp\u003ECristofanilli M, Rugo SH, Im SA, et al. Overall Survival With Palbociclib \u002B Fulvestrant in Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Updated Analyses From PALOMA-3. Presented at: The American Society of Clinical Oncology (ASCO) 2021 Annual Meeting Virtual; June 4-8, 2021; Abstract 1000.\u003C/p\u003E",
  "37": "\u003Cp\u003EPrat A, Chaudhury A, Solovieff N, et al. Correlative Biomarker Analysis of Intrinsic Subtypes and Efficacy Across the MONALEESA Phase III Studies. J Clin Oncol. 2021;39:1458-1467. doi: 10.1200/JCO.2\u003C/p\u003E\u003Cp\u003EPurchase link:\u003C/p\u003E\u003Cp\u003Ehttps://articleworks.cadmus.com/buy?c=1608355\u0026url_back=http://ascopubs.org/doi/abs/10.1200/JCO.20.02977\u0026url=http://ascopubs.org/doi/pdf/10.1200/JCO.20.02977\u0026journal=jco\u0026volume=39\u0026issue_number=13\u0026cover_date=May%201,%202021\u0026startpage=1458\u0026pages=11\u0026title=Correlative%20Biomarker%20Analysis%20of%20Intrinsic%20Subtypes%20and%20Efficacy%20Across%20the%20MONALEESA%20Phase%20III%20Studies\u0026authors=\u003C/p\u003E",
  "38": "\u003Cp\u003EBinghe X, Zhang Q, Zhang P, et al. Dalpiciclib versus placebo plus fulvestrant in HR\u002B/HER2- advanced breast cancer thatrelapsed or progressed on previous endocrine therapy (DAWNA-1): A multicenter,randomized, phase 3 study. Presented at: ASCO 2021 Annual Meeting; June 4-8, 2021. Abstract 1002.\u003C/p\u003E",
  "39": "",
  "40": "\u003Cp\u003ECristofanilli M, Turner NC, Bondarenko I, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016;17:425-439. doi: 10.1016/S1470-2045(15)00613-0. Epub 2016 Mar 3. Erratum in: Lancet Oncol. 2016 Apr;17 (4):e136. Erratum in: Lancet Oncol. 2016 Jul;17 (7):e270. PMID: 26947331.\u003C/p\u003E\u003Cp\u003ESlamon DJ, Neven P, Chia S, et al. Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3. J Clin Oncol. 2018;36:2465-2472. doi: 10.1200/JCO.2018.78.9909. Epub 2018 Jun 3. PMID: 29860922.\u003C/p\u003E\u003Cp\u003ESledge GW Jr, Toi M, Neven P, et al. MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR\u002B/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. J Clin Oncol. 2017;35:2875-2884. doi: 10.1200/JCO.2017.73.7585. Epub 2017 Jun 3. PMID: 28580882.\u003C/p\u003E",
  "41": "",
  "42": "",
  "43": "\u003Cp\u003EFUL = fulvestrant\u003C/p\u003E\u003Cp\u003ERIB = ribociclib\u003C/p\u003E\u003Cp\u003EOS = overall survival \u003C/p\u003E\u003Cp\u003ESlamon DJ, et al. Presented at: ASCO Virtual; 2021. Abstract 1001.\u003C/p\u003E\u003Cp\u003ESlamon DJ, Neven P, Chia SKL, et al. Updated overall survival (OS) results from the phase III MONALEESA-3 trial of postmenopausal patients (pts) with HR\u002B/HER2- advanced breast cancer (ABC) treated with fulvestrant (FUL) \u00B1 ribociclib (RIB). Presented at: The American Society of Clinical Oncology (ASCO) 2021 Annual Meeting Virtual; June 4-8, 2021; Abstract 1001.\u003C/p\u003E",
  "44": "\u003Cp\u003EPascual J, et al. Presented at: ASCO Virtual; 2021. Abstract 1014.\u003C/p\u003E\u003Cp\u003EPascual J, Gil-Gil M, Zielinski C, et al. CCNE1 mRNA and cyclin E1 protein expression as predictive biomarkers for efficacy of palbociclib plus fulvestrant versus capecitabine in the phase III PEARL study. Presented at: The American Society of Clinical Oncology (ASCO) 2021 Annual Meeting Virtual; June 4-8, 2021; Abstract 1014.\u003C/p\u003E",
  "45": "",
  "46": "",
  "47": "\u003Cp\u003EYardley DA. Common AEs associated with CDK4/6 inhibitors in patients with hormone receptor-positive advanced breast cancer. J Clin Oncol. 2017;35:239-239.\u003C/p\u003E\u003Cp\u003EAbbreviations: \u003C/p\u003E\u003Cp\u003ETRAE = treatment-related adverse event\u003C/p\u003E\u003Cp\u003EOS = overall survival\u003C/p\u003E\u003Cp\u003EPFS = progression-free survival\u003C/p\u003E",
  "48": "",
  "49": "",
  "50": ""
}